Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer

Summary

The purpose of this study is to determine if treatment with Darolutamide plus androgen deprivation therapy (ADT) before radical prostatectomy (RP) with pelvic lymph node dissection (pLND) in participants with high-risk localized or locally advanced prostate cancer results in an improvement in pathological complete response (pCR) rate and pathological tumor volume with minimal residual disease (MRD)) as compared to ADT.

Timeline

Start

2024-05-01

Primary completion

2026-05

Completion

2029-05

Drugs

Indications